1 / 13

Consumer Directed Health Plans and Disparities in Prescription Drug Use

Jessica Greene PhD Judith Hibbard DrPH. Consumer Directed Health Plans and Disparities in Prescription Drug Use. Background. CDHPs combine a high deductible health plan with a health care account, and informational resources

charlton-alberto
Download Presentation

Consumer Directed Health Plans and Disparities in Prescription Drug Use

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Jessica Greene PhD Judith Hibbard DrPH Consumer Directed Health Plans and Disparities in Prescription Drug Use

  2. Background • CDHPs combine a high deductible health plan with a health care account, and informational resources • CDHPs were designed to spark more informed health care decision making • Some have voiced concern over CDHPs’ impact on vulnerable populations • “If consumer-directed plans achieve market dominance, disparities in care by class and race will probably grow” (Bloche, Health Affairs 2007) • “Simply put, cost sharing results in de facto discrimination” (Rice, National Academies Press 2003)

  3. Cost Sharing & Racial/Ethnic Disparities Little evidence, suggests race/ethnicity may matter, but not always in expected direction • Black women with Medicare had higher mammogram levels under cost sharing than white women (Trivedi et al., NEJM 2008) • Minorities were three times more likely to restrict pharmacy use when they had no prescription coverage than whites (Steinman et al., JGIM 2001)

  4. Cost Sharing & Socio-demographic Disparities Little evidence, inconsistent findings, limited by relatively homogenous employed populations and proxy income measures • After enrolling in a CDHP, hourly employees more likely to cut back on office visits than salaried, including high priority acute care visits (Hibbard et al. forthcoming) • Women residing in low income areas were more likely than those in higher income areas to reduce mammogram use when subject to cost-sharing (Trivedi et al. NEJM 2008) • No difference found in some studies (Cherkin et al. Soc Sci Med 1992 & Chandra et al. NBER 2007)

  5. Research Question Are people of different backgrounds (race/ethnicity or socio-economic status) differentially impacted by CDHP enrollment? • This builds on prior work that has found that CDHP enrollees are more likely to discontinue some chronic illness medications

  6. Plan Details

  7. Methods • Compared discontinuation of 3 classes of chronic disease medication (antidiabetics, antihypertensives and lipid lowering drugs) among whites/minorities and hourly/salaried in two periods: • Baseline period (7/2003-12/2003) n=3,515 • Intervention period (1/2004-12/2004) n=3,785 • Discontinuation was defined as not purchasing any of the drug class in observation period, but had purchased in prior 6 months and had 1 day supplied in prior 60 days • Propensity weights adjusted for differences in health and socio-demographics of those enrolling in CDHPs

  8. Discontinuation Rates by Race/Ethnicity Intervention 12.6 37.3* Intervention 7.2 8.1 Intervention 6.3 7.3

  9. Discontinuation Rates by Socioeconomic Status Intervention 15.8 15.0 Intervention 7.5 7.3 Intervention 4.5 7.1

  10. Summary • Enrollment in CDHP resulted in greater discontinuation of chronic illness drugs for minority enrollees than whites • May increase disparities in health outcomes • No difference in discontinuation rates in CDHP between hourly and salaried enrollees

  11. Limitations • Small numbers of minority enrollees in the CDHP • Using claims as measure of taking chronic illness medications • Short time frame (1st year of enrollment) • This is the experience of 1 employer and CDHP market is rapidly changing

  12. Implications • Plans should routinely monitor high deductible CDHP enrollees (and others) for discontinuation & send alerts • Plans should monitor racial/ethnic and SES differences in discontinuation • Employers should strongly consider first dollar coverage for preventive medications currently allowed in the HSA regulations • Congress should revisit allowing first dollar coverage in HSAs for chronic illness medications

  13. The authors wish to acknowledge both the participating employer and CDHP for their openness and commitment to research. We also would like to thank “The Changes in Health Care Financing and Organization” (HCFO), a program of The Robert Wood Johnson Foundation, for providing support for this research. And we would like to thank Merck for prior support on related work. Acknowledgements

More Related